ID
27985
Description
NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma. Study part: Prior + concomitant diseases. Visit: All visits. Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz
Keywords
Versions (2)
- 12/7/17 12/7/17 -
- 1/1/18 1/1/18 -
Copyright Holder
Prof. Dr. med. Georg Heß
Uploaded on
December 7, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Diseases GOAL Trial B-cell Lymphoma NCT02499003
Diseases GOAL Trial B-cell Lymphoma NCT02499003
- StudyEvent: ODM
Description
Prior + Concomitant Diseases
Description
Disease number
Data type
integer
Description
Disease specification
Data type
text
Description
Start date
Data type
date
Description
Stop date
Data type
date
Description
Ongoing disease at End of Treatment
Data type
boolean
Similar models
Diseases GOAL Trial B-cell Lymphoma NCT02499003
- StudyEvent: ODM
No comments